File Download
 
 
Supplementary

Conference Paper: High efficacy of high intensity focused ultrasound without transarterial embolization for hepatocellular carcinoma
  • Basic View
  • Metadata View
  • XML View
TitleHigh efficacy of high intensity focused ultrasound without transarterial embolization for hepatocellular carcinoma
 
AuthorsNg, KKC
Poon, RTP
Cheung, TT
Chu, FSK
Tso, WK
Fan, ST
 
Issue Date2009
 
PublisherInternational Liver Cancer Association.
 
CitationThe 3rd Annual Conference of the International Liver Cancer Association (ILCA), Milan, Italy, 4-6 September 2009. In Abstracts Book of the 3rd ILCA, 2009, p. 48, abstract no. P-123 [How to Cite?]
 
AbstractBACKGROUND: High-intensity focused ultrasound (HIFU) is a new non-invasive treatment modality for unresectable hepatocellular carcinoma (HCC). Transarterial embolization (TAE) before HIFU has been used to increase the efficacy of ablation, but there are disadvantages associated with this approach. OBJECTIVES: This study aims to evaluate the outcome of patients with HCC after HIFU with and without pre-treatment TAE. METHODS: From October 2006 to April 2008, HIFU was performed in 41 patients with unresectable HCC. Twenty-one patients received TAE two weeks before HIFU in the initial phase of study (period 1), whereas 20 patients underwent HIFU alone in the latter phase of study (period 2). Treatment efficacy was compared between two groups. RESULTS: There were no significant differences between two groups in patient demographic and clinicopathologic parameters. The median size of largest tumor was similar in period 1 and period 2 (2.7cm versus 2.1cm). Both groups received similar amount of energy from HIFU. The overall mortality rate was 2.4% and the overall complication rate was 12.1%. The complete tumor ablation rate in period 2 was significantly higher than that in period 1 (95% vs. 65%, P = 0.044). Taking into consideration of the total number of ablated tumor nodules, the complete ablation rate in period 2 was 96%, which was significantly higher than that in period 1 (68%). (P = 0.020) The overall recurrence rate was 44.4%. There was no significant difference in recurrence rate between patients in period 1 (56.2%) and period 2 (35%) (P = 0.501). Short-term survival outcome between the two groups (period 1 vs. period 2) were similar (86.5% vs. 79% at 1 year, P = 0.074). CONCLUSION: HIFU without pre-treatment TAE is more effective than combined treatment approach in terms of high complete tumor ablation rate. HIFU treatment is a promising treatment modality for patients with unresectable HCC.
 
DescriptionPoster Presentation: abstract no. P-123
 
DC FieldValue
dc.contributor.authorNg, KKC
 
dc.contributor.authorPoon, RTP
 
dc.contributor.authorCheung, TT
 
dc.contributor.authorChu, FSK
 
dc.contributor.authorTso, WK
 
dc.contributor.authorFan, ST
 
dc.date.accessioned2010-10-31T12:57:06Z
 
dc.date.available2010-10-31T12:57:06Z
 
dc.date.issued2009
 
dc.description.abstractBACKGROUND: High-intensity focused ultrasound (HIFU) is a new non-invasive treatment modality for unresectable hepatocellular carcinoma (HCC). Transarterial embolization (TAE) before HIFU has been used to increase the efficacy of ablation, but there are disadvantages associated with this approach. OBJECTIVES: This study aims to evaluate the outcome of patients with HCC after HIFU with and without pre-treatment TAE. METHODS: From October 2006 to April 2008, HIFU was performed in 41 patients with unresectable HCC. Twenty-one patients received TAE two weeks before HIFU in the initial phase of study (period 1), whereas 20 patients underwent HIFU alone in the latter phase of study (period 2). Treatment efficacy was compared between two groups. RESULTS: There were no significant differences between two groups in patient demographic and clinicopathologic parameters. The median size of largest tumor was similar in period 1 and period 2 (2.7cm versus 2.1cm). Both groups received similar amount of energy from HIFU. The overall mortality rate was 2.4% and the overall complication rate was 12.1%. The complete tumor ablation rate in period 2 was significantly higher than that in period 1 (95% vs. 65%, P = 0.044). Taking into consideration of the total number of ablated tumor nodules, the complete ablation rate in period 2 was 96%, which was significantly higher than that in period 1 (68%). (P = 0.020) The overall recurrence rate was 44.4%. There was no significant difference in recurrence rate between patients in period 1 (56.2%) and period 2 (35%) (P = 0.501). Short-term survival outcome between the two groups (period 1 vs. period 2) were similar (86.5% vs. 79% at 1 year, P = 0.074). CONCLUSION: HIFU without pre-treatment TAE is more effective than combined treatment approach in terms of high complete tumor ablation rate. HIFU treatment is a promising treatment modality for patients with unresectable HCC.
 
dc.description.naturelink_to_OA_fulltext
 
dc.descriptionPoster Presentation: abstract no. P-123
 
dc.description.otherThe 3rd Annual Conference of the International Liver Cancer Association (ILCA), Milan, Italy, 4-6 September 2009. In Abstracts Book of the 3rd ILCA, 2009, p. 48, abstract no. P-123
 
dc.identifier.citationThe 3rd Annual Conference of the International Liver Cancer Association (ILCA), Milan, Italy, 4-6 September 2009. In Abstracts Book of the 3rd ILCA, 2009, p. 48, abstract no. P-123 [How to Cite?]
 
dc.identifier.epage48
 
dc.identifier.hkuros180773
 
dc.identifier.spage48
 
dc.identifier.urihttp://hdl.handle.net/10722/126936
 
dc.languageeng
 
dc.publisherInternational Liver Cancer Association.
 
dc.relation.ispartofAbstracts Book of the Annual Conference of the International Liver Cancer Association, ILCA 2009
 
dc.titleHigh efficacy of high intensity focused ultrasound without transarterial embolization for hepatocellular carcinoma
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Ng, KKC</contributor.author>
<contributor.author>Poon, RTP</contributor.author>
<contributor.author>Cheung, TT</contributor.author>
<contributor.author>Chu, FSK</contributor.author>
<contributor.author>Tso, WK</contributor.author>
<contributor.author>Fan, ST</contributor.author>
<date.accessioned>2010-10-31T12:57:06Z</date.accessioned>
<date.available>2010-10-31T12:57:06Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>The 3rd Annual Conference of the International Liver Cancer Association (ILCA), Milan, Italy, 4-6 September 2009. In Abstracts Book of the 3rd ILCA, 2009, p. 48, abstract no. P-123</identifier.citation>
<identifier.uri>http://hdl.handle.net/10722/126936</identifier.uri>
<description>Poster Presentation: abstract no. P-123</description>
<description.abstract>BACKGROUND: High-intensity focused ultrasound (HIFU) is a new non-invasive treatment modality for unresectable hepatocellular carcinoma (HCC). Transarterial embolization (TAE) before HIFU has been used to increase the efficacy of ablation, but there are disadvantages associated with this approach. OBJECTIVES: This study aims to evaluate the outcome of patients with HCC after HIFU with and without pre-treatment TAE. METHODS: From October 2006 to April 2008, HIFU was performed in 41 patients with unresectable HCC. Twenty-one patients received TAE two weeks before HIFU in the initial phase of study (period 1), whereas 20 patients underwent HIFU alone in the latter phase of study (period 2). Treatment efficacy was compared between two groups. RESULTS: There were no significant differences between two groups in patient demographic and clinicopathologic parameters. The median size of largest tumor was similar in period 1 and period 2 (2.7cm versus 2.1cm). Both groups received similar amount of energy from HIFU. The overall mortality rate was 2.4% and the overall complication rate was 12.1%. The complete tumor ablation rate in period 2 was significantly higher than that in period 1 (95% vs. 65%, P = 0.044). Taking into consideration of the total number of ablated tumor nodules, the complete ablation rate in period 2 was 96%, which was significantly higher than that in period 1 (68%). (P = 0.020) The overall recurrence rate was 44.4%. There was no significant difference in recurrence rate between patients in period 1 (56.2%) and period 2 (35%) (P = 0.501). Short-term survival outcome between the two groups (period 1 vs. period 2) were similar (86.5% vs. 79% at 1 year, P = 0.074). CONCLUSION: HIFU without pre-treatment TAE is more effective than combined treatment approach in terms of high complete tumor ablation rate. HIFU treatment is a promising treatment modality for patients with unresectable HCC.</description.abstract>
<language>eng</language>
<publisher>International Liver Cancer Association.</publisher>
<relation.ispartof>Abstracts Book of the Annual Conference of the International Liver Cancer Association, ILCA 2009</relation.ispartof>
<title>High efficacy of high intensity focused ultrasound without transarterial embolization for hepatocellular carcinoma</title>
<type>Conference_Paper</type>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.hkuros>180773</identifier.hkuros>
<identifier.spage>48</identifier.spage>
<identifier.epage>48</identifier.epage>
<description.other>The 3rd Annual Conference of the International Liver Cancer Association (ILCA), Milan, Italy, 4-6 September 2009. In Abstracts Book of the 3rd ILCA, 2009, p. 48, abstract no. P-123</description.other>
<bitstream.url>http://hub.hku.hk/bitstream/10722/126936/1/re01.htm</bitstream.url>
</item>